GAO Weighs In on Accountability, Responsible Uses; FDA Raises Questions About AI and Clinical Trials
Darla M. Fera
May 27, 2023 at 09:36:48 ET
“Artificial intelligence (AI) is evolving at a rapid pace” and the federal government and other stakeholders, including academia, “cannot afford to be reactive to its complexities, risks and societal consequences,” according to the Government Accountability Office (GAO) in a recent report, and this may be particularly true as AI is integrated into federally supported research activi...
Read More